title: Chemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma.
abstract: Case reports of pulmonary toxicity have been published regarding bortezomib, lenalidomide, and thalidomide but there are no published reports looking at the possible long-term pulmonary effects of these medications. This article describes a possible relationship between the administration of bortezomib and thalidomide and the development of pulmonary function test (PFT) abnormalities. It also suggests that routine pulmonary function testing may be required in patients receiving these medications until larger studies can be performed to confirm this observation.
  
  
  BACKGROUND
  Multiple myeloma is a common malignancy accounting for approximately 1% of all malignancies worldwide. Bortezomib, lenalidomide, and thalidomide are immunomodulatory derivatives that are used in the treatment of multiple myeloma (MM). There have been case reports of pulmonary disease associated with these agents, but the effect of these agents on pulmonary function test (PFT) results is unknown.
  
  
  METHODS
  We reviewed the records of 343 patients with MM who underwent PFTs before autologous stem cell transplantation. One hundred nine patients had not received any of the 3 medications, whereas 234 had received 1 or more of these agents.
  
  
  RESULTS
  Patients exposed to bortezomib were more likely to have obstructive PFT results (P = .015) when compared with patients not exposed to this medication. Restrictive PFT results were more likely after exposure to thalidomide (P = .017). A logistic regression model was performed and when adjusted for age, sex, Durie-Salmon (DS) stage, body mass index (BMI), time from diagnosis to transplantation in days, and smoking history, the odds of obstruction were 1.96 times higher for patients who received bortezomib. The odds of restriction were 1.97 times higher after exposure to thalidomide.
  
  
  CONCLUSIONS
  There appears to be a risk of PFT abnormalities developing in patients treated with bortezomib and thalidomide.
authors.affiliation: Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, the Ohio State University Medical Center, Columbus, OH, USA.
authors.forename: Jarrod T
authors.initials: JT
authors.lastname: Bruce
authors.forename: Jerry M
authors.initials: JM
authors.lastname: Tran
authors.forename: Gary
authors.initials: G
authors.lastname: Phillips
authors.forename: Pat
authors.initials: P
authors.lastname: Elder
authors.forename: John G
authors.initials: JG
authors.lastname: Mastronarde
authors.forename: Steven M
authors.initials: SM
authors.lastname: Devine
authors.forename: Craig C
authors.initials: CC
authors.lastname: Hofmeister
authors.forename: Karen L
authors.initials: KL
authors.lastname: Wood
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001897:Boronic Acids / Q000009:adverse effects / Q000627:therapeutic use; D000069286:Bortezomib; D005260:Female; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000009:adverse effects / Q000627:therapeutic use; D012129:Respiratory Function Tests / Q000379:methods; D012307:Risk Factors; D013792:Thalidomide / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib